Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndromes

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2015 by Celgene Corporation
Information provided by (Responsible Party):
Celgene Corporation Identifier:
First received: April 17, 2013
Last updated: September 11, 2015
Last verified: September 2015
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2016
  Estimated Primary Completion Date: August 2016 (Final data collection date for primary outcome measure)